Toretsky JA - Search Results

1

Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A. Minas TZ, et al. Among authors: toretsky ja. Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388. Oncotarget. 2017. PMID: 27191748 Free PMC article.

2

Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.

Uren A, Merchant MS, Sun CJ, Vitolo MI, Sun Y, Tsokos M, Illei PB, Ladanyi M, Passaniti A, Mackall C, Toretsky JA. Uren A, et al. Among authors: toretsky ja. Oncogene. 2003 Apr 17;22(15):2334-42. doi: 10.1038/sj.onc.1206330. Oncogene. 2003. PMID: 12700668

3

Preparation of F-18 labeled annexin V: a potential PET radiopharmaceutical for imaging cell death.

Toretsky J, Levenson A, Weinberg IN, Tait JF, Uren A, Mease RC. Toretsky J, et al. Nucl Med Biol. 2004 Aug;31(6):747-52. doi: 10.1016/j.nucmedbio.2004.02.007. Nucl Med Biol. 2004. PMID: 15246365

4

Wnt/Frizzled signaling in Ewing sarcoma.

Uren A, Wolf V, Sun YF, Azari A, Rubin JS, Toretsky JA. Uren A, et al. Among authors: toretsky ja. Pediatr Blood Cancer. 2004 Sep;43(3):243-9. doi: 10.1002/pbc.20124. Pediatr Blood Cancer. 2004. PMID: 15266408

5

Recombinant EWS-FLI1 oncoprotein activates transcription.

Uren A, Tcherkasskaya O, Toretsky JA. Uren A, et al. Among authors: toretsky ja. Biochemistry. 2004 Oct 26;43(42):13579-89. doi: 10.1021/bi048776q. Biochemistry. 2004. PMID: 15491164

6

Pediatric malignancies provide unique cancer therapy targets.

Uren A, Toretsky JA. Uren A, et al. Among authors: toretsky ja. Curr Opin Pediatr. 2005 Feb;17(1):14-9. doi: 10.1097/01.mop.0000147904.84978.ae. Curr Opin Pediatr. 2005. PMID: 15659957 Review.

7

PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis.

Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. Abaan OD, et al. Among authors: toretsky ja. Oncogene. 2005 Apr 14;24(16):2715-22. doi: 10.1038/sj.onc.1208247. Oncogene. 2005. PMID: 15782144

8

Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.

Uren A, Toretsky JA. Uren A, et al. Among authors: toretsky ja. Future Oncol. 2005 Aug;1(4):521-8. doi: 10.2217/14796694.1.4.521. Future Oncol. 2005. PMID: 16556028 Review.

9

Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A.

Toretsky JA, Erkizan V, Levenson A, Abaan OD, Parvin JD, Cripe TP, Rice AM, Lee SB, Uren A. Toretsky JA, et al. Cancer Res. 2006 Jun 1;66(11):5574-81. doi: 10.1158/0008-5472.CAN-05-3293. Cancer Res. 2006. PMID: 16740692

10

Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.

Aryee DN, Kreppel M, Bachmaier R, Uren A, Muehlbacher K, Wagner S, Breiteneder H, Ban J, Toretsky JA, Kovar H. Aryee DN, et al. Among authors: toretsky ja. Cancer Res. 2006 Oct 15;66(20):9862-9. doi: 10.1158/0008-5472.CAN-05-4042. Cancer Res. 2006. PMID: 17047047

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

124 results

Search Page